Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06625320
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06624085
- Locations
- 🇺🇸
Saddleback Memorial Medical Center, Laguna Hills, California, United States
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States
🇺🇸Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, United States
🇦🇺Tasman Oncology Research ( Site 2104), Southport, Queensland, Australia
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 530
- Registration Number
- NCT06619236
A Phase 1b Study of TTF in Combination With Durvalumab and GemCis in BTC.
- Conditions
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 60
- Registration Number
- NCT06611345
- Locations
- 🇨🇳
Anhui Provincial Hospital, He Fei, China
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇨🇳
Hsin-Chu Hospital, Hsin-chu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT06608927
- Locations
- 🇺🇸
Clinical Research Alliance, New Hyde Park, New York, United States
🇺🇸Summit Cancer Centers - Spokane Valley, Spokane, Washington, United States
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 43
- Registration Number
- NCT06597565
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT06586515
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸City of Hope Medical Group, South Pasadena, California, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
LSTA1 Phase 1b/2a Continuous Infusion Trial in MPDAC
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06592664
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Spartanburg Medical Center, Spartanburg, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.